Quelante Deferasirox
Pongo textual:
Deferasirox offers an important treatment option for people with thalassaemia and secondary iron overload. Based on the available data, deferasirox does not seem to be superior to deferoxamine at the usually recommended ratio of 1 mg of deferasirox to 2 mg of deferoxamine. However, similar efficacy seems to be achievable depending on the dose and ratio of deferasirox compared to deferoxamine. Whether this will result in similar efficacy and will translate to similar benefits in the long term, as has been shown for deferoxamine, needs to be confirmed. Data from randomised controlled trials on rare toxicities and long-term safety are still limited. However, after a detailed discussion of the potential benefits and risks, deferasirox could be offered as the first-line option to individuals who show a strong preference for deferasirox, and may be a reasonable treatment option for people showing an intolerance or poor adherence to deferoxamine.
Este quelante se administra por vía oral, ingresa al torrente sanguíneo, y captura el hierro. Luego se elimina porla materia fecal.
No está aprobado para hemocromatosis, entiendo que se considera que un uso de por vida sería tóxico para el organismo, ya que se ha visto que puede provocar problemas renales.
Sería muy interesante encontrar una molécula más simple que cumpliera esta misma función.
Deferasirox offers an important treatment option for people with thalassaemia and secondary iron overload. Based on the available data, deferasirox does not seem to be superior to deferoxamine at the usually recommended ratio of 1 mg of deferasirox to 2 mg of deferoxamine. However, similar efficacy seems to be achievable depending on the dose and ratio of deferasirox compared to deferoxamine. Whether this will result in similar efficacy and will translate to similar benefits in the long term, as has been shown for deferoxamine, needs to be confirmed. Data from randomised controlled trials on rare toxicities and long-term safety are still limited. However, after a detailed discussion of the potential benefits and risks, deferasirox could be offered as the first-line option to individuals who show a strong preference for deferasirox, and may be a reasonable treatment option for people showing an intolerance or poor adherence to deferoxamine.
Este quelante se administra por vía oral, ingresa al torrente sanguíneo, y captura el hierro. Luego se elimina porla materia fecal.
No está aprobado para hemocromatosis, entiendo que se considera que un uso de por vida sería tóxico para el organismo, ya que se ha visto que puede provocar problemas renales.
Sería muy interesante encontrar una molécula más simple que cumpliera esta misma función.
Comentarios
Publicar un comentario